ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc (ALDX)

3.70
-0.09
(-2.37%)
Closed May 29 4:00PM
3.71
0.01
(0.27%)
After Hours: 7:59PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
3.70
Bid
3.66
Ask
3.72
Volume
256,031
3.675 Day's Range 3.8098
1.42 52 Week Range 11.97
Market Cap
Previous Close
3.79
Open
3.73
Last Trade
20
@
3.72
Last Trade Time
Financial Volume
$ 955,193
VWAP
3.7308
Average Volume (3m)
545,571
Shares Outstanding
58,895,768
Dividend Yield
-
PE Ratio
-5.82
Earnings Per Share (EPS)
-0.64
Revenue
-
Net Profit
-37.54M

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye dis... Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Aldeyra Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALDX. The last closing price for Aldeyra Therapeutics was $3.79. Over the last year, Aldeyra Therapeutics shares have traded in a share price range of $ 1.42 to $ 11.97.

Aldeyra Therapeutics currently has 58,895,768 shares outstanding. The market capitalization of Aldeyra Therapeutics is $218.50 million. Aldeyra Therapeutics has a price to earnings ratio (PE ratio) of -5.82.

ALDX Latest News

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today...

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

Clinical Results and Potential New Drug Application Submission Expected in the Second Half of 2024 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to...

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

Live Webcast Scheduled to Begin at 9 am EDT Today Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial...

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today...

Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases...

Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.23-5.85241730283.933.993.6752717543.83554032CS
4-0.26-6.565656565663.964.383.6553214884.01420417CS
12-0.27-6.801007556683.974.972.715455713.87786222CS
261.0137.54646840152.694.972.697533493.49435661CS
52-5.73-60.76352067879.4311.971.4213221234.27146742CS
156-8.83-70.470869912212.5313.181.429494815.45841288CS
260-3.42-48.03370786527.1215.951.428901386.86070743CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.9393
(129.10%)
576.2M
BNAIBrand Engagement Network Inc
$ 2.6062
(105.21%)
108.22M
ONCOOnconetix Inc
$ 0.2949
(79.93%)
137.82M
ASTSAST SpaceMobile Inc
$ 9.0199
(69.23%)
109.9M
KTRAKintara Therapeutics Inc
$ 0.272
(44.76%)
81.59M
FFIEFaraday Future Intelligent Electric Inc
$ 0.4379
(-62.57%)
417.92M
AWINAERWINS Technologies Inc
$ 5.555
(-39.22%)
2.01M
HLTHCue Health Inc
$ 0.0553
(-38.96%)
72.11M
GWAVGreenwave Technology Solutions Inc
$ 0.0494
(-37.15%)
676.15M
PLTNUPlutoniam Acquisition Corporation
$ 5.83
(-34.57%)
965
GWAVGreenwave Technology Solutions Inc
$ 0.0494
(-37.15%)
676.15M
LUCYInnovative Eyewear Inc
$ 0.9393
(129.10%)
576.2M
FFIEFaraday Future Intelligent Electric Inc
$ 0.4379
(-62.57%)
417.92M
RSLSReShape Lifesciences Inc
$ 0.2847
(37.01%)
212.55M
AALAmerican Airlines Group Inc
$ 11.62
(-13.54%)
159.16M

ALDX Discussion

View Posts
Monksdream Monksdream 2 months ago
ALDX under $4
πŸ‘οΈ0
jgrabar jgrabar 2 months ago
NOTICE TO LONG-TERM ALDEYRA THERAPEUTICS, INC. (NASDAQ: ALDX) INVESTORS

Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of FMC have breached their fiduciary duties owed to the company.

Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to January 7, 2021 should click here: https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/. You can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to you whatsoever.

Why: A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, it is alleged that the Company made false and misleading statements about or failed to disclose: (i) the ADX-2191 new drug application (β€œNDA”) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, Aldeyra had overstated ADX-2191's clinical and/or commercial prospects; and (iv) as a result, Aldeyra’s public statements were materially false and misleading at all relevant times.

If you have continuously held Aldeyra shares since prior to January 7, 2021, you are encouraged to visit https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/, contact Joshua H. Grabar at jgrabar @FH-6085.
πŸ‘οΈ0
InvestorPhilia4 InvestorPhilia4 2 months ago
Still progressing here. I think they have been prudent, of late... with the AbbVie option agreement for Reproxalap and other shots on goal without partners. There is certainly upside with continued clinical success. Any updated views on Aldeyra?
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
InvestorPhilia4 InvestorPhilia4 7 months ago
I added 3,500 shares on 10/16 as well below $1.80. I wish I leaned in more. I am a holder and still see long-term upside from here.
πŸ‘οΈ0
Invest-in-America Invest-in-America 7 months ago
ALDX: Just crossed the (dangerous) 1.5-Hrs-Into-The-Open-Rubicon, and movin' UP from there!! (Not easy to do for ANY stock.)
πŸ‘οΈ0
green maschine green maschine 7 months ago
Nice grab. It's good to be the early bird. I knew nothing about the company, just saw the news.
πŸ‘οΈ0
Invest-in-America Invest-in-America 7 months ago
Me too, Dude. (And this Firm has worked on this drug for a long time; and that ain't NO 'small-potatoes' Company that just partnered with them either.)

πŸ‘οΈ0
green maschine green maschine 7 months ago
Yep. I snatched up some of this pre-market.
πŸ‘οΈ0
Invest-in-America Invest-in-America 7 months ago
ALDX: Could have a good day here; 'Dry Eye' syndrome afflicts MILLIONS worldwide!
πŸ‘οΈ0
Investor2014 Investor2014 7 months ago
I bought to average down today, it seems a sensible move.
πŸ‘οΈ0
InvestorPhilia4 InvestorPhilia4 7 months ago
With the pending readouts and relatively short trials that may provide additional support, I agree.

Also, the company has some breathing room with > $2 per share in cash after all liabilities as of 6/30 and only burning ~ $0.20 per share quarterly.

The current sub $2 share price looks attractive to me.
πŸ‘οΈ0
Investor2014 Investor2014 7 months ago
Ouch indeed, but it isn’t over for dry eye and we are expecting one other different P3 indication readout this year.
πŸ‘οΈ0
InvestorPhilia4 InvestorPhilia4 7 months ago
Ouch
πŸ‘οΈ0
Investor2014 Investor2014 11 months ago
A not so great day yesterday for $ALDX.

Small potential indication costing the 25% run up we have in expectation of H2 events.

It isn’t over for ADX-2191 yet though…
πŸ‘οΈ0
InvestorPhilia4 InvestorPhilia4 1 year ago
I have been invested here (smaller position than in AVXL) also. Binary/inflection points appear to be ahead mid-2023. We appear to have several shots on goal.
πŸ‘οΈ0
Investor2014 Investor2014 2 years ago
Yet another great day for aldeyra.

No one invested here?
πŸ‘οΈ0
Investor2014 Investor2014 2 years ago
Another great day for Aldeyra. In due course probably pay handsomely.
πŸ‘οΈ0
Investor2014 Investor2014 2 years ago
Good day for Aldeyra!
πŸ‘οΈ0
Investor2014 Investor2014 2 years ago
That’s biotech.
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
what I meant was the time line

mid 2022

πŸ‘οΈ0
Investor2014 Investor2014 2 years ago
Agree and believe that is what I just said.
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
yeah but heres the kicker

ALDX
Primary Endpoint of TRANQUILITY-2 Trial Modified to be Met if Either Ocular Redness or Schirmer Test Achieved; Target Enrollment Increased from 300 to up to 400 Patients; Top-Line Results Expected Mid-2022
πŸ‘οΈ0
Investor2014 Investor2014 2 years ago
So TRANQUILITY-2 endpoints to be changed to meet either Redness or Schirmer for potential approval.

Could be fine not least given that secondary p-value.

Still hope!
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
ALDX NEWS https://www.streetinsider.com/Business+Wire/Aldeyra+Therapeutics+Announces+Top-Line+Results+from+the+Phase+3+TRANQUILITY+Trial+in+Dry+Eye+Disease/19374659.html
πŸ‘οΈ0
Investor2014 Investor2014 2 years ago
Yeah not good.
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
NEWS HALT ))) 12/20/2021 16:00:34 ALDX Aldeyra Therapeutics Cmn Stk NASDAQ
T1
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
Looks like the market finally clicked that ocular redness is the primary endpoint over the conventional Schirmer’s test as agreed by the FDA trial protocol.

πŸ‘οΈ0
Rayn_Makr Rayn_Makr 3 years ago
ADX-1612 and ADX-1615, Chaperome Inhibitors

Last summer I dove into the mechanism of action for ADX-1612 and spent a fair amount of time looking at HSP90 on PubMed. It is a widely recognized target. It will be interesting to see how the numerous assets at ALDX are managed. It's challenging to put a market cap and time to reach that value but they have great potential, no doubt. Current market conditions will probably make for a wild ride. Good Luck!

https://pubmed.ncbi.nlm.nih.gov/?term=hsp90+inhibitor
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
I agree, ALDX has great potential.
πŸ‘οΈ0
Rayn_Makr Rayn_Makr 3 years ago
RASP-INHIBITION IN SYSTEMIC DISEASES

ADX-629 became a topic in the recent conference call so I did a revisit of that therapeutic. Glad I did since ADX-629 offers an impressive opportunity to further RASP inhibition. Several nuggets to pass along from a quick review of ADX-629:

The clinical trial NCT04847544 for Treatment of COVID-19 was initiated in April. It is recruiting N=30 and estimated completion this year.

https://clinicaltrials.gov/ct2/show/NCT04847544?term=aldeyra&recrs=abdf&draw=2&rank=1

Secondly, the phase 1 results showed target engagement "Also Improved Lipid Profiles". Lipid therapeutics have a large market, i.e., cardiovascular disease. Look at slide #17.

https://ir.aldeyra.com/static-files/33742ce3-ebdc-4569-9f65-b5b7bd8c73eb

The asthma trial is also on the trial list.

https://clinicaltrials.gov/ct2/results?term=aldeyra&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=&Search=Apply%5D

Six ongoing clinical trials explains the recent raise in capital and great timing on that. Kudos to management!
πŸ‘οΈ0
Rayn_Makr Rayn_Makr 3 years ago
Perceptive Advisors SEC form 4
3 May 2021 shows 1,200,000 shares bought at $12.50 = $15,000,000
They now have a total of 9.9 million shares which at $12.50 = $123,750,000. They have been adding since July 2020. Safe to say they have a positive outlook, eh?
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
It will stay above the $12.50 offer price just like last time especially given the great P3 trial readout.
πŸ‘οΈ0
make it happen make it happen 3 years ago
I wouldn't touch this personally with a ten foot stick for a while not bashing but that's a heck of a lot of dilution coming out. 125 million dollars and able to add a lot more.
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
Bought in again @$12.89.
πŸ‘οΈ0
make it happen make it happen 3 years ago
Huge $125,000,000 offering & can add another $18,750,000 million
πŸ‘οΈ0
make it happen make it happen 3 years ago
Most def
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
Sold today avg $15.07. Figured they’d needmore funding and the price would dip waiting for a NDA filing and next P3 readout in H2.

Plenty time to buy back in cheaper, which should be a nice long term hold.
πŸ‘οΈ0
ClayTrader ClayTrader 3 years ago
* * $ALDX Video Chart 04-27-2021 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
make it happen make it happen 3 years ago
Good volume. When it slows it'll fade hard imho Wish could get locates some where. 4x highest volume day ever
πŸ‘οΈ0
altruism altruism 3 years ago
Billion dollars traded today so far
πŸ‘οΈ0
make it happen make it happen 3 years ago
Yes, usually have something going on or at least some kind revenues from something. Not just spending money.
πŸ‘οΈ0
altruism altruism 3 years ago
Looking GOOD
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
You seem surprised. Ever invested in pre-revenue biotechs?
πŸ‘οΈ0
make it happen make it happen 3 years ago
Hmmm 0 profit, 0 revenus, debt, negative cash flow, with a $1.52 book value.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) 0.00%

Management Effectiveness
Return on Assets (ttm) -27.28%
Return on Equity (ttm) -69.81%

Income Statement
Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) N/A
EBITDA -34.61M
Net Income Avi to Common (ttm) -37.55M
Diluted EPS (ttm) -1.11
Quarterly Earnings Growth (yoy) N/A

Balance Sheet
Total Cash Per Share (mrq) 1.12
Total Debt (mrq) 15.33M
Total Debt/Equity (mrq) 25.76
Current Ratio (mrq) 6.69
Book Value Per Share (mrq) 1.54

Cash Flow Statement
Operating Cash Flow (ttm) -37.49M
Levered Free Cash Flow (ttm) -20.28M
πŸ‘οΈ0
l2 hunter l2 hunter 3 years ago
ALDX $15.30 +37%
πŸ‘οΈ0
l2 hunter l2 hunter 3 years ago
ALDX $14.50 +30%
πŸ‘οΈ0
Rayn_Makr Rayn_Makr 3 years ago
This article supports the narrative that ALDX provides, namely, the current products for dry eye take a long time to have any effect and hard to keep people from discontinuing use.

https://www.ajmc.com/view/evolving-knowledge-of-the-unmet-needs-in-dry-eye-disease
πŸ‘οΈ0
Rayn_Makr Rayn_Makr 3 years ago
The close on Friday, 3/19/2021
I watched the market on Fidelity Active Trader Pro and ALDX was at ~500,000 shares at 3:40 today and hit 1,000,000 by 3:58. When I looked at it after the close, 4,200,000 so in the last minute or two, 3 million shares at $12/share or $36 million. What's up with that? Somebody wanted 3 million shares without moving the price? How can that volume be executed in a minute or two? I could believe 50 - 100 k shares but 3 million? An issue with Fidelity showing volume? Please enlighten me.
πŸ‘οΈ0
l2 hunter l2 hunter 3 years ago
ALDX $14.45 looks very good now. Strong breakout setting for next big upward move
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock